NCT05464173: Chidamide in Combination With Abemaciclib and Fulvestrant in Breast Cancer Patients Previously Treated With Palbociclib

NCT05464173
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy or fulvestrant (or fulvestrant-resistant) for recurrent or metastatic breast cancer; Patients with more than 3 lines of prior endocrine therapy; Patients with prior HDAC inhibitor therapy or any other CDK inhibitor that is not Ibrance (e.g. Kisqali/ribociclib, Verzenio/abemaciclib); Patients that have not progressed while taking Ibrance/palbociclib in the neoadjuvant setting or at least 6 months into the metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05464173

NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not received prior Herceptin/trastuzumab with progression of the disease; Patients with symptomatic, untreated, or progressive central nervous system metastases
https://ClinicalTrials.gov/show/NCT05429684

Up ↑